Literature DB >> 26754826

Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply.

T Bernal1, P Martínez-Camblor1,2, J Sánchez-García3, G Sanz4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26754826     DOI： 10.1038/leu.2015.339

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  3 in total

1.  Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: results from the Dutch population-based PHAROS MDS registry.

Authors:  A G Dinmohamed; Y van Norden; O Visser; E F M Posthuma; P C Huijgens; P Sonneveld; A A van de Loosdrecht; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2015-09-15       Impact factor: 11.528

2.  Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry.

Authors:  T Bernal; P Martínez-Camblor; J Sánchez-García; R de Paz; E Luño; B Nomdedeu; M T Ardanaz; C Pedro; M L Amigo; B Xicoy; C del Cañizo; M Tormo; J Bargay; D Valcárcel; S Brunet; L Benlloch; G Sanz
Journal:  Leukemia       Date:  2015-05-06       Impact factor: 11.528

3.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316
  3 in total
  1 in total

1.  Effectiveness of azacitidine in higher-risk myelodysplastic syndromes.

Authors:  A G Dinmohamed; Y van Norden; A A van de Loosdrecht; M Jongen-Lavrencic
Journal:  Leukemia       Date:  2016-05-20       Impact factor: 11.528
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.